Kosmos Energy Ltd. Common Shares (DE) vs Regeneron Pharmaceuticals Inc — how do they compare? Kosmos Energy Ltd. Common Shares (DE) trades at $2.71 (market cap $1.66B), while Regeneron Pharmaceuticals Inc trades at $784.4 (market cap $77.54B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 46.7× Kosmos Energy Ltd. Common Shares (DE)'s market cap, and Regeneron Pharmaceuticals Inc pays a 0.5% dividend while Kosmos Energy Ltd. Common Shares (DE) pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kosmos Energy Ltd. Common Shares (DE) for 0 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| KOS | REGN | |
|---|---|---|
Market Cap | $1.66B | $77.54B |
Volume | 7,535,344 | 629,519 |
Sector | Energy | Health |
52-Week High | $3.27 | $852.03 |
52-Week Low | $0.87 | $569.17 |
Typical Hold Time | 0 Days | 107 Days |
Enterprise Value | $4.30B | $72.25B |
Dividend Yield | — | 0.5% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Regeneron Pharmaceuticals (REGN) trades at $778.36, up 2.04% on the day, with a bullish technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights a significant expansion of its immunology alliance with Sanofi, valued up to $8 billion, which could drive future growth. Valuation ratios appear reasonable, with a P/E of 18.64 and robust profitability margins.
The outlook for REGN is positive, supported by strong earnings momentum, a lucrative partnership expansion, and a unanimous analyst buy consensus. Key risks include competitive pressures in the biopharma space and reliance on key drug performance. The stock presents a compelling opportunity for growth investors, with a consensus price target of $849.84 suggesting upside potential.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Kosmos Energy Ltd. is a deepwater oil and gas exploration and production company with operations offshore Ghana, Equatorial Guinea, Mauritania, and Senegal in West Africa.
Read more on KOS →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →